Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
| ▸ | RRM1 | P23921 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 2/20 | 0.36 |
| ▸ | FNTB | P49356 | 2/20 | 0.36 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29971461 | 0.86 | DPP7 (0.40) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL31258939 | 0.83 | DPP7 (0.47) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL30381897 | 0.80 | DPP7 (0.47) | DPP7FOLH1GNAI3GNAO1GNAI1 | |
| SCHEMBL31680489 | 0.80 | PTGS1 (0.40) | DPP7DPP4DPP8DPP9ALDH1A1 | |
| SCHEMBL29376151 | 0.80 | KDM4E (0.50) | DPP7FOLH1GNAI3GNAO1GNAI1 | |
| SCHEMBL30958905 | 0.79 | NPY4R (0.50) | — | |
| SCHEMBL31091497 | 0.79 | DPP4 (0.53) | FOLH1DPP4DPP8DPP9ALDH1A1 | |
| SCHEMBL30350525 | 0.79 | SLC1A3 (0.40) | DPP7DPP4DPP8DPP9ALDH1A1 | |
| SCHEMBL29579811 | 0.78 | SMN1; SMN2 (0.49) | DPP7FOLH1GNAI3GNAO1GNAI1 | |
| SCHEMBL236178 | 0.77 | KDM4E (0.56) | DPP7FOLH1KDM4EMAPK1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845808-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | JANSSEN BIOTECH, INC. (US) | 2023-12-19 | — | — | US | claimed |
| CN-115298196-A | Peptide inhibitors of the interleukin-23 receptor and their use for the treatment of inflammatory diseases | 詹森生物科技公司 | 2022-11-04 | — | — | CN | claimed |
| CN-114341161-A | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases | 领导医疗有限公司 | 2022-04-12 | — | — | CN | claimed |
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12552836-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4613761-A9 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4613761-A2 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4090670-B1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH INC (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4547337-A1 | NEW PEPTIDES AS SELECTIVE IL-23 RECEPTOR ANTAGONISTS | Sanofi (FR) | 2025-05-07 | — | — | EP | disclosed |
| WO-2024003313-A9 | NEW PEPTIDES AS SELECTIVE IL-23 RECEPTOR ANTAGONISTS | SANOFI (FR) | 2025-03-20 | — | — | WO | disclosed |
| US-20240409598-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH INC (US) | 2024-12-12 | — | — | US | disclosed |
| US-11845808-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | JANSSEN BIOTECH, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| CN-116082455-A | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases | 领导医疗有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20230129095-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| EP-4090670-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| CN-115298196-A | Peptide inhibitors of the interleukin-23 receptor and their use for the treatment of inflammatory diseases | 詹森生物科技公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20220251142-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2022-08-11 | — | — | US | disclosed |
| EP-3997105-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Protagonist Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-114341161-A | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases | 领导医疗有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20220041658-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251142-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | DPP7 358/4885FOLH1 640/4885GNAI3 551/4885 |
| US-20230129095-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | DPP7 358/4885FOLH1 640/4885GNAI3 551/4885 |
| US-12552836-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL17A, IL36G | DPP7 826/4885FOLH1 1213/4885GNAI3 2682/4885 |
| US-20220041658-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | DPP7 358/4885FOLH1 640/4885GNAI3 551/4885 |
| US-20240409598-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL1RN, IL36G | DPP7 2451/4885FOLH1 301/4885GNAI3 1510/4885 |
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, IL36G | DPP7 175/4885FOLH1 3178/4885GNAI3 2706/4885 |
| US-11845808-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL1RN, VIP | DPP7 358/4885FOLH1 640/4885GNAI3 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.